Capstan: The Story of the Open Minds Behind the Acquisition of an In Vivo CAR-T Pioneer

When Capstan Therapeutics agreed to be acquired by AbbVie for a record-breaking price of $2.1B upfront, it had just started its Phase 1 study in healthy volunteers, was well-capitalized, and was on a mission to put a range of autoimmune diseases into deep remission and maybe even cure them. Some people will wonder about the significance of this deal and what lessons it may have for their own ventures. We can share our insights. We’ve been on the Capstan journey since the beginning and are incredibly proud of the team and its work. This is a story worth hearing.